Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1 Data show a nearly 50 percent reduction in disease progression in BRCA-altered mHSPC1 BEERSE, BELGIUM, June 03, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson announced today first results from the Phase 3, randomised, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in patien ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with placebo plus ADT XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with meta ...